Massive study checks if diabetes Drug's heart benefits hold up outside the lab
NCT ID NCT03363464
First seen Jan 18, 2026 · Last updated Apr 25, 2026 · Updated 12 times
Summary
This study tracks over 230,000 adults with type 2 diabetes to see how well empagliflozin works in everyday medical practice. Researchers are comparing it to another class of diabetes drugs (DPP-4 inhibitors) to measure real-world effects on heart attacks, strokes, heart failure, and death. The goal is to confirm whether benefits seen in earlier clinical trials translate to a broader, more diverse patient population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bringham Women Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.